Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma

J Clin Oncol. 2023 Jan 20;41(3):443-446. doi: 10.1200/JCO.22.01770. Epub 2022 Sep 26.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Ipilimumab / adverse effects
  • Melanoma* / drug therapy
  • Nivolumab / adverse effects
  • Skin Neoplasms* / drug therapy

Substances

  • Ipilimumab
  • Nivolumab